Catalog11 refs
ARA-290
Immune ModulationtherapeuticHealing & RecoveryCognitiveResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Body Map
nervesSkinCirculationtissues
Overview
ARA-290 (cibinetide) is a synthetic 11-amino-acid peptide derived from the tissue-protective region of erythropoietin (EPO), engineered to calm inflammation and repair nerves without thickening the blood. It selectively activates the innate repair receptor (IRR), dampening inflammatory signaling and reducing cell death while leaving red blood cell production alone. It has been tested in Phase 2 human trials for sarcoidosis-related small fiber neuropathy and diabetic neuropathy, holding FDA Orphan Drug and Fast Track designation, but was never approved and development has stalled.
Primary Uses
Nerve pain
Small fiber neuropathy
Sarcoidosis
Metabolic syndrome
Neuropathic pain reduction
Small nerve fiber repair and regeneration
Anti-inflammatory signaling
Metabolic parameter improvement in type 2 diabetes
Tissue repair
Neuropathic pain treatment
Diabetic neuropathy
Sarcoidosis-associated small nerve fiber loss
Anti-inflammatory therapy
Small fiber nerve regeneration
Neuropathic pain models
Small-fiber neuropathy research
Innate repair receptor signaling
Anti-inflammatory tissue-protection studies
Metabolic control in type 2 diabetes
Diabetic macular edema
Alzheimer's disease-like pathology
Transplanted islet protection
Cardiac ischemia imaging (SPECT tracer)
Osteoarthritis / joint injuries
Neuroprotection
Peripheral Nerve Regeneration
Diabetic Neuropathy Treatment
CNS Protection
Wound Healing
Cardiovascular Protection
Anti-Aging Effects
Cytokine Reduction
IBD Support
Transplant Protection
Tissue repair and regeneration
Nerve regeneration
Protection against ischemia-reperfusion injury
Improving vascular function
Sarcoidosis-related small fiber neuropathy
Neuropathic pain relief
Improvement of hemoglobin A1c and lipid profile
Corneal nerve fiber regeneration
Skin nerve fiber regeneration
Protocol Reference
Dose
2-5mg
Frequency
Once Daily (daily Protocol) Or 3x Per Week (maintenance)
Half-life
~11 Minutes
Route
Subcutaneous
Evidence
Phase 2 completed, development stalled / Phase 2 / Phase 2 clinical trials / Extensively Studied / Clinical trials ongoing (disputed)
Research References· 19
Research Models
Human
Also in Immune Modulation